Will GLP-1 Drugs Change the Way We Think About Addiction?
- 21 hours ago
- 4 min read
Claudia Gravaghi is a Nutritional Scientist, Product Formulator and Counsellor in metabolic health. She combines clinical research, biochemistry, and emotional behavioural support to guide individuals, including GLP-1 users, toward sustainable health, metabolic balance, and a more informed relationship with food.
For decades, society has explained addiction with a remarkably simple narrative. People overeat because they lack discipline. People drink because they lack self-control. People smoke because they simply haven't tried hard enough to stop.
Whether the addiction involves food, alcohol, nicotine, or gambling, the underlying message has often been the same, if you really wanted to change, you would. But what if this narrative has always been incomplete?"
The emergence of GLP-1 receptor agonists may be doing more than changing the treatment of obesity. They may be forcing us to reconsider one of our oldest assumptions about human behaviour, that addiction is primarily a failure of willpower.
A changing conversation
Only a few decades ago, depression was commonly misunderstood. Many people believed it reflected weakness, a lack of resilience, or simply a negative attitude.
Today, neuroscience has transformed that conversation. We recognise depression as a complex condition influenced by genetics, neurobiology, life experiences, and environment. Psychological support remains essential, but very few clinicians would argue that people simply need to "try harder." Could addiction be following a similar path?
The brain does not distinguish between morality and biology
One of the greatest advances in neuroscience has been our understanding of the brain's reward system. Eating, drinking, social connection, and other rewarding behaviours activate neural pathways designed to reinforce survival.
For some individuals, however, these circuits become dysregulated. Genetics, chronic stress, trauma, metabolic disease, and environmental factors can all influence how intensely reward is experienced and how difficult it becomes to disengage from a particular behaviour.
This does not remove personal responsibility, but it does suggest that biology deserves a seat at the table alongside psychology and behaviour.
Why GLP-1 therapies are changing the discussion
Originally developed to improve glucose regulation and later used in obesity treatment, GLP-1 receptor agonists have produced an unexpected observation. Many individuals report not only reduced hunger but also fewer intrusive thoughts about food. Some describe a reduced desire for alcohol. Others report changes in other reward-driven behaviours.
Although research is still evolving, these observations are encouraging scientists to explore whether GLP-1 signalling influences brain networks involved in motivation, reward, and reinforcement.
This does not mean that GLP-1 medications are a cure for addiction, nor does it mean that every compulsive behaviour shares the same biological mechanism. However, it raises an important question, "If changing a biological pathway can reduce the intensity of certain compulsive urges, how much of what we have traditionally labelled "willpower" is actually biology?"
Beyond the medication
As both a nutritional scientist and counsellor, I find this question particularly important. Medication may reduce the intensity of a craving, but it does not automatically resolve the emotional experiences, learned behaviours, or life circumstances that gave that behaviour meaning.
Someone who has used food to cope with loneliness, anxiety, or chronic stress may experience less biological drive to eat while taking GLP-1 therapy. But when the medication changes, those emotional needs do not simply disappear.
This is why I believe the future of obesity and addiction treatment lies in integration rather than replacement. Biology creates opportunity. Behaviour determines whether that opportunity becomes lasting change.
From judgement to curiosity
Perhaps the greatest contribution of GLP-1 therapies will not ultimately be measured in kilograms lost. Perhaps their greatest contribution will be the questions they force us to ask.
What if people struggling with compulsive eating were never simply lacking discipline? What if biology and behaviour have always been working together? What if understanding the brain allows us to replace judgement with curiosity?
These questions extend far beyond obesity. They challenge how we think about addiction itself.
Looking ahead
Science rarely changes society overnight. It changes the questions we ask first.
GLP-1 therapies may not eliminate addiction, nor should they replace psychological care or behavioural support. But they are helping us recognise something profoundly important, human behaviour is rarely explained by willpower alone.
The more we understand the dialogue between metabolism, the brain, and behaviour, the closer we come to treatments that are not only more effective but also more compassionate. Perhaps that is the real revolution.
Read more from Claudia Gravaghi
Claudia Gravaghi, Nutritional Scientist, Formulator & Counsellor
Claudia Gravaghi is a Nutritional Scientist, Product Formulator, and Counsellor with a PhD in Clinical Nutrition and a background in pharmaceutical chemistry. She has worked internationally as a postdoctoral researcher in nutrition, metabolism, and cancer. Today, she develops evidence-based formulations and supports individuals in improving both metabolic health and their relationship with food. She has a particular focus on individuals using GLP-1 medications, helping them navigate appetite changes, nutritional adequacy, and the emotional aspects of eating. Her work bridges molecular science and real-life behaviour, translating complex biochemistry into practical, personalised strategies.
